<div id="readability-page-1"><p>OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CEO Matthew Foehr sold 13,666 shares of the business's stock in a transaction on Monday, December 8th. The shares were sold at an average price of $1.96, for a total value of $26,785.36. Following the completion of the sale, the chief executive officer owned 4,360,083 shares in the company, valued at $8,545,762.68. This represents a 0.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.</p><h2>OmniAb Price Performance</h2><p>NASDAQ OABI opened at $1.99 on Tuesday. The company has a market cap of $286.48 million, a P/E ratio of -3.43 and a beta of 0.13. The stock has a 50-day moving average of $1.65 and a two-hundred day moving average of $1.71. OmniAb, Inc. has a 1-year low of $1.22 and a 1-year high of $4.17. </p><p>OmniAb (NASDAQ:OABI - Get Free Report) last issued its quarterly earnings results on Tuesday, November 4th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01. The business had revenue of $2.24 million for the quarter, compared to analysts' expectations of $5.64 million. OmniAb had a negative net margin of 301.83% and a negative return on equity of 23.14%.  On average, analysts anticipate that  OmniAb, Inc. will post -0.61 EPS for the current fiscal year. </p><h2>Hedge Funds Weigh In On OmniAb</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nuveen LLC acquired a new stake in  OmniAb during the first quarter worth approximately $547,000.  Public Employees Retirement System of Ohio purchased a new position in shares of  OmniAb in the 2nd quarter valued at $168,000.  PNC Financial Services Group Inc. raised its stake in  OmniAb by 279.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,276 shares of the company's stock worth $39,000 after acquiring an additional 11,986 shares in the last quarter.  Connors Investor Services Inc. lifted its position in  OmniAb by 25.0% in the second quarter. Connors Investor Services Inc. now owns 62,000 shares of the company's stock valued at $108,000 after acquiring an additional 12,389 shares during the last quarter.  Finally, Towerview LLC boosted its stake in  OmniAb by 43.3% in the second quarter. Towerview LLC now owns 831,100 shares of the company's stock valued at $1,446,000 after acquiring an additional 251,100 shares in the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds. </p><h2>Analyst Ratings Changes</h2><p>Separately, Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of OmniAb in a research note on Monday, December 1st. Three investment analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $6.67.</p><p><b>View Our Latest Research Report on OABI</b></p><h2>OmniAb Company Profile</h2> (Get Free Report)<p>OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than OmniAb</li><li>What is a Low P/E Ratio and What Does it Tell Investors?</li><li>Why These 3 Automotive &amp; Industrial Chip Stocks Just Soared</li><li>What is the Dow Jones Industrial Average (DJIA)?</li><li>Top 5 Highest-Rated Dividend Stocks, According to MarketBeat</li><li>Election Stocks: How Elections Affect the Stock Market</li><li>What Dollar Tree’s Surge and Home Depot’s Slide Say About Consumer Health</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0FCSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in OmniAb Right Now?</h2><p>Before you consider OmniAb, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.</p><p>While OmniAb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

OABI

<p>OmniAb CEO Matthew Foehr sold 13,666 shares for $26,785.36, reducing his stake by 0.31%. Post-sale, he owns 4,360,083 shares valued at $8,545,762.68. The transaction was disclosed in an SEC filing. OmniAb's stock opened at $1.99, with a market cap of $286.48 million. Analysts rate the stock as "Moderate Buy" with a target price of $6.67. Institutional investors hold 72.08% of the stock.</p>

OmniAb (NASDAQ:OABI) CEO Sells $26,785.36 in Stock